These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35988850)

  • 1. Macrolide therapy in Pseudomonas aeruginosa infections causes uL4 ribosomal protein mutations leading to high-level resistance.
    Goltermann L; Andersen KL; Johansen HK; Molin S; La Rosa R
    Clin Microbiol Infect; 2022 Dec; 28(12):1594-1601. PubMed ID: 35988850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Macrolide therapy in Pseudomonas aeruginosa infections causes uL4 ribosomal protein mutations leading to high-level resistance: author's response.
    Goltermann L; Johansen HK; Molin S; La Rosa R
    Clin Microbiol Infect; 2022 Dec; 28(12):1667-1668. PubMed ID: 36150672
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: 'Macrolide therapy in Pseudomonas aeruginosa infections causes uL4 ribosomal protein mutations leading to high-level resistance' by Goltermann et al.
    Karakonstantis S
    Clin Microbiol Infect; 2022 Dec; 28(12):1665-1666. PubMed ID: 36075497
    [No Abstract]   [Full Text] [Related]  

  • 4. Acquired resistance to macrolides in
    Mustafa MH; Khandekar S; Tunney MM; Elborn JS; Kahl BC; Denis O; Plésiat P; Traore H; Tulkens PM; Vanderbist F; Van Bambeke F
    Eur Respir J; 2017 May; 49(5):. PubMed ID: 28526799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory effects of macrolides on bacterial virulence: potential role as quorum-sensing inhibitors.
    Tateda K; Standiford TJ; Pechere JC; Yamaguchi K
    Curr Pharm Des; 2004; 10(25):3055-65. PubMed ID: 15544497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of Two Macrolide Resistance-Related Genes in Multidrug-Resistant
    Chen Q; Lu W; Zhou D; Zheng G; Liu H; Qian C; Zhou W; Lu J; Ni L; Bao Q; Li A; Xu T; Xu H
    Pol J Microbiol; 2020 Sep; 69(3):349-356. PubMed ID: 33574864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aminoglycoside resistance of Pseudomonas aeruginosa in cystic fibrosis results from convergent evolution in the mexZ gene.
    Prickett MH; Hauser AR; McColley SA; Cullina J; Potter E; Powers C; Jain M
    Thorax; 2017 Jan; 72(1):40-47. PubMed ID: 27325751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.
    Ciofu O
    APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scorpionfish BPI is highly active against multiple drug-resistant
    Holzinger JM; Toelge M; Werner M; Ederer KU; Siegmund HI; Peterhoff D; Blaas SH; Gisch N; Brochhausen C; Gessner A; Bülow S
    Elife; 2023 Jul; 12():. PubMed ID: 37461324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Macrolide antibiotics for cystic fibrosis.
    Southern KW; Barker PM; Solis A
    Cochrane Database Syst Rev; 2004; (2):CD002203. PubMed ID: 15106170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Penicillin-binding protein 3 is a common adaptive target among Pseudomonas aeruginosa isolates from adult cystic fibrosis patients treated with β-lactams.
    Clark ST; Sinha U; Zhang Y; Wang PW; Donaldson SL; Coburn B; Waters VJ; Yau YCW; Tullis DE; Guttman DS; Hwang DM
    Int J Antimicrob Agents; 2019 May; 53(5):620-628. PubMed ID: 30664925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does ivacaftor interfere with the antimicrobial activity of commonly used antibiotics against Pseudomonas aeruginosa?-Results of an in vitro study.
    Millar BC; Rendall JC; Downey DG; Moore JE
    J Clin Pharm Ther; 2018 Dec; 43(6):836-843. PubMed ID: 29959786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pseudomonas aeruginosa syntrophy in chronically colonized airways of cystic fibrosis patients.
    Qin X; Zerr DM; McNutt MA; Berry JE; Burns JL; Kapur RP
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5971-81. PubMed ID: 22964251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucoidy, quorum sensing, mismatch repair and antibiotic resistance in Pseudomonas aeruginosa from cystic fibrosis chronic airways infections.
    Feliziani S; Luján AM; Moyano AJ; Sola C; Bocco JL; Montanaro P; Canigia LF; Argaraña CE; Smania AM
    PLoS One; 2010 Sep; 5(9):. PubMed ID: 20844762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2015 Nov; (11):CD006961. PubMed ID: 26522473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Smith S; Waters V; Jahnke N; Ratjen F
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD009528. PubMed ID: 32520436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD009528. PubMed ID: 28981972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2015 Mar; (3):CD009528. PubMed ID: 25741986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genotypic and phenotypic analyses of a Pseudomonas aeruginosa chronic bronchiectasis isolate reveal differences from cystic fibrosis and laboratory strains.
    Varga JJ; Barbier M; Mulet X; Bielecki P; Bartell JA; Owings JP; Martinez-Ramos I; Hittle LE; Davis MR; Damron FH; Liechti GW; Puchałka J; dos Santos VA; Ernst RK; Papin JA; Albertí S; Oliver A; Goldberg JB
    BMC Genomics; 2015 Oct; 16():883. PubMed ID: 26519161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function.
    Tramper-Stranders GA; Wolfs TF; Fleer A; Kimpen JL; van der Ent CK
    Pediatr Infect Dis J; 2007 Jan; 26(1):8-12. PubMed ID: 17195698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.